Asthma Patient Articles & Analysis
57 news found
It is an important treatment not only for asthma patients, but for otolaryngology and pediatrics in a variety of settings as well. ...
Sulfites can trigger allergy-like reactions to sensitized people, such as wheezing in those suffering from asthma, allergic rhinitis, and urticaria[3]. Additionally, we can find other hidden allergens in beverages, such as pine nuts in craft beer, almonds in some gins, milk in cream liquors, or wheat in beers and spirits. Patients and clinicians must be ...
In the U.S., Dupixent is approved in patients aged 6 years and older with uncontrolled moderate-to-severe atopic dermatitis; as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma; and for use with ...
"We are excited to bring the well-established safety and efficacy profile of Dupixent to even younger patients living with uncontrolled severe asthma in Europe. In addition to greatly reducing severe asthma attacks and improving lung function, patients in our clinical trials also reduced their oral corticosteroid use. ...
Cohort A showed a promising safety and efficacy profile in previously untreated patients and cohort B has the potential demonstrate the first clinical study results in the emerging population of prior bevacizumab and atezolizumab treated patients. ...
To date, the majority of the patients prescribed FOTIVDA have been 4th line or later. We expect later line patients to generally exhibit higher early discontinuation rates. ...
“Public Reimbursment access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a ...
“Enerzair and Atectura are both valuable additions to the Canadian asthma treatment landscape and we are looking forward to working with all remaining jurisdictions across the country to ensure broad patient access”. ...
TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma ...
Patent protected wireless lung function testing technology, Asthma, COPD, and post-COVID syndrome, Spirometry market is predicted to double in 12 months, Globalisation initiative – Europe, SE Asia and the US. Uscom notifies the market of notice to approve CE mark for the Uscom digital ultrasonic SpiroSonic AIR spirometer. The CE mark is recognition of legal compliance with health, safety ...
The test will further help Siolta identify and monitor patients eligible for their live biotherapeutic therapy currently under development. More than 4 million children suffer from asthma in the US. It is estimated that 30 – 35% of infants in the US are born into families with a history of allergy and asthma. ...
The test will further help Siolta identify and monitor patients eligible for their live biotherapeutic therapy currently under development. More than 4 million children suffer from asthma in the US. It is estimated that 30 – 35% of infants in the US are born into families with a history of allergy and asthma. ...
ByBio-Me
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy ...
The Journal of Asthma published the results of a study that assessed asthma patients and their ability to perform high-quality daily spirometry with the AioCare system. ...
ByAioCare
Fifty adult patients diagnosed with severe eosinophilic asthma (defined by blood eosinophilia ≥300 cells / μl and at least three asthma exacerbations in the previous year) will be recruited for the study. ...
ByAioCare
This new medical propellant has been under development for several years for use in metered-dose inhalers (MDIs) for treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). Zephex® 152a reduces the carbon footprint of an MDI, helping to safeguard an invaluable therapeutic option for patients. ...
ByKoura
In a recent study, 10 patients with unstable, severe asthma were treated with Bronchial Thermoplasty (BT) of the left lung, while the right lung was used as an internal control. ...
ByFluidda
We will now seek out strategic partners who share our goal of improving the lives of patients who have allergic disease. While immunotherapy has long been recognized as the only allergy therapy that targets the underlying immune condition, subcutaneous and sublingual immunotherapy have limitations for many patients. The sad result is that far too many allergic ...
Work-related asthma results from exposure to allergens or irritants on the job. Exposure to these substances can lead to new cases of asthma or worsen existing asthma in some people. The National Institutes of Health (NIH) details that more than 250 substances are known or believed to cause or exacerbate work-related asthma (occupational asthma). These substances are found in many chemicals, ...
Babies, kids and the elderly are especially at risk for breathing diseases for many reasons. They are very susceptible to breathing diseases, all the more we should invest in protecting them from what may cause it. Protect Babies and Elderly from Breathing Diseases The elderly usually suffer from asthma but are often explained as old age. It could also be caused by smoking or bad air quality ...
ByuHoo